Stem Cell Authority, Ltd.
SCAL
Other OTC0.00
USD
- -
- -
ISIN
US85857C1080
CUSIP
85857C108
Return %
Stock
S&P500
1Y
0.00
18.02
3Y
-60.00
64.11
5Y
-97.33
72.15
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Chong Yi Yang
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- 123 South Miller Road Fairlawn OH People's Republic of China 44333
- IPO Date
- Mar 17, 2005
- Website
- stemcellauthority.com
- Similar Companies
- Business
- Stem Cell Authority, Ltd. (Ticker: SCAL) is a biotechnology company specializing in the development, manufacturing, and marketing of stem cell preservation and regenerative medicine products and services. The company offers core products including umbilical cord blood and tissue preservation services, stem cell banking solutions, and related medical storage products designed to support advanced regenerative therapies. Stem Cell Authority operates primarily in the healthcare and life sciences industry, targeting families and individuals seeking long-term biological insurance for future medical applications. Founded in 2014 and headquartered in the United States, Stem Cell Authority has expanded its operations regionally with a focus on North America. The company continuously innovates in stem cell collection, processing, and storage technologies. In the last 1 to 2 years, Stem Cell Authority has formed strategic partnerships to broaden its service network and enhance clinical service offerings, introduced new stem cell therapy-related products, and increased its presence in the regenerative medicine market. These developments reflect a strategic shift towards integrated service delivery combining banking and therapeutic application facilitation. Stem Cell Authority operates as a public company listed under the ticker SCAL, serving a diverse customer base including hospitals, clinics, and individual consumers interested in cellular therapies. The company maintains compliance with regulatory standards relevant to biobanking and medical product storage and engages in continuous research and development to improve product efficacy and customer service. Its business segments focus on stem cell collection, biological sample storage, and supporting clinical regenerative treatments, establishing Stem Cell Authority as a notable player in the regenerative medicine and biotechnology sectors.